ArticleNature communications2023

Signature-driven repurposing of Midostaurin for combination with MEK1/2 and KRASG12C inhibitors in lung cancer.

Irati Macaya et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.